Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology (NYSE:LLY)

INDIANAPOLIS and LYON, France, Dec. 19, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Adocia (Euronext Paris: FR0011184241 - ADOC) today announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. BioChaperone Lispro relies on Adocia's proprietary BioChaperone® technology and is currently in Phase Ib studies.



Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology (NYSE:LLY)